Nan Li

Founder @_DimensionCap

[Nan Li @nanli]

1/ Last March, I teamed up with @AGoulburn and @zavaindar to build a new venture firm from scratch.

Beyond excited to officially launch Dimension (@_DimensionCap), a firm completely dedicated to the intersection of technology and the life sciences.

https://t.co/vJOMRAEZi3

[Zavain Dar @zavaindar]

2 years ago Chai was a small team led by @joshim5 & @jackdent working out of the Dimension offices

today they are leading the charge to reinvigorate western pharma and biotech. Lilly and Pfizer are partners. the majority of pharma queuing up..

the rate of progress: staggering

[Joshua Meier @joshim5]

Today we are announcing our collaboration with Pfizer to put Chai's frontier AI—including our latest model, Chai-3—directly into the hands of one of the world's leading pharmaceutical teams.

[Jack Dent @jackdent]

I’m delighted to announce @chaidiscovery's collaboration with @pfizer. Their scientists will deploy our AI platform to accelerate drug discovery, including early access to our latest frontier model Chai-3.

You can learn more about this partnership and our momentum in @amyfeldman's feature in @Forbes out today

https://t.co/VBoynDgPCz

[Bauer LeSavage @bauer_lesavage]

The training data market has exploded for LLMs and bio foundation models are next.

But biological data is extremely complex and requires a data generation playbook that prioritizes quality over immediate scale.

@_DimensionCap Research article live now!

https://t.co/3CqSYADLJP

[NewLimit @newlimit]

Following breakthrough results, we’re bringing longevity medicine to human trials.

We’ve raised a $435M Series C led by @foundersfund to make it happen.

Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it.

[Deniz Kavi @kavi_deniz]

ESMFold2 and the ESM-C family, now available for use!

We’ve partnered with @biohub (the ESM team’s new home), to provide day 1 access to their newly open-sourced series of models. The family of models show best-in-class results for structure prediction, de novo design, and protein-language model tasks.

[Sri Kosuri @srikosuri]

This is so cool!

[Nan Li @nanli]

Great post from @Convokebio mapping out the wide set of opportunities that exist in drug discovery. Most have no or suboptimal treatments, so much opportunity to develop medicines that impact patients!

[Convoke @Convokebio]

Today we're publishing our index of unmet needs in human disease: 2443 indications scored and ranked on burden of disease, prevalence, pipeline activity, and treatment burden. We hope this will help drug developers identify overlooked medical problems

https://t.co/OX4BKC8cfI

[Convoke @Convokebio]

Today we're publishing our index of unmet needs in human disease: 2443 indications scored and ranked on burden of disease, prevalence, pipeline activity, and treatment burden. We hope this will help drug developers identify overlooked medical problems

https://t.co/OX4BKC8cfI

[Nan Li @nanli]

Milestone moment for Odyssey Therapeutics as a publicly traded company! Testament to the incredible team and science behind the company and we are excited for the next chapter ahead! $ODTX

[DIMENSION @_DimensionCap]

Congrats to Gary Glick and the entire Odyssey Therapeutics team on today’s upsized IPO! We’re thrilled to deepen our partnership with the team as they aim to redefine the standard of care for patients living with autoimmune and inflammatory diseases. https://t.co/hzG6871reo

[Nan Li @nanli]

@semil @haystackvc @aashaysanghvi_ @DivyaDhulipala Congrats!!

[Nan Li @nanli]

Excited to announce @_DimensionCap's partnership with @apoorva_mehta @LakshAithani and @olshav on Abundance!

A fully-integrated AI stack to drive scientific and technical underwriting, eval'd against the real time feedback of the public markets. This is an idea whose time has come, headed by an incredible group of founders. Congrats on the launch and much more to come!

[Apoorva Mehta @apoorva_mehta]

https://t.co/Mavrl0rGww

[Nan Li @nanli]

RT @zavaindar: it's been exhilarating being a day 0 investor & partner with @apoorva_mehta @LakshAithani and @olshav as they build ABUNDAN…

[Nan Li @nanli]

Continue to be blown away at the pace of development at @tamarindbio. They are cooking!!

[Deniz Kavi @kavi_deniz]

We've launched 300+ molecular AI models on Tamarind.

Today, we're giving you the system we use to do it.

Introducing Custom Tools 🧵

[Georgia Channing @cgeorgiaw]

the blogs that @tamarindbio write legitimately make it possible to understand the whole landscape from one article

every other field needs this, and no other field has it

[Nan Li @nanli]

Secret’s out on @_DimensionCap’s very own @nikhilvnamburi! Deeply curious, truth seeking, competitive investor. Great to have him on the team!

Find an excuse to meet with him in SF, NY, or an obscure database conference near you.

[Delta Institute @DeltaInstitutes]

Join us in recognizing Delta's Rising Investors of 2026! 🎉

Congrats to the investors our community nominated as truly exceptional at the early stage. Angels, emerging fund managers, and established names alike, recognized for their track records, the depth of their writing, and their presence in the technical community.

These are the people who cut through the noise, back the right companies early, and show up as real partners to the founders they work with.

https://t.co/ghOMXmnNEe

[Deniz Kavi @kavi_deniz]

Today we announce the Tamarind Bio assay portal: The wet lab, now driven by software

We’ve partnered with @AAlphaBio, @adaptyvbio, and @Ginkgo to bring protein and antibody assays directly into Tamarind, making it much easier to move from computational design to real experimental feedback.

Protein design is not bottlenecked by generating candidates, but by validating them quickly enough to learn from them. We’re starting with the workhorse experiments: protein-protein binding affinity characterization, developability, expression, and stability.

The Assay Portal helps scientists:
Get fast, low-friction, cost-effective validation of designed proteins and antibodies, transparent pricing without needing separate MSAs
Specialize models on their own experimental data for affinity maturation, developability, and property optimization
Run lab-in-the-loop campaigns where each assay result improves the next design cycle
Turn wet lab data into model training infrastructure, including RL environments and large-scale datasets for pretraining

As computational molecular design matures, we believe integration between wet lab feedback and continuous learning will yield the highest quality results. That’s why we’re excited to bring the unique, differentiated capabilities of our partners to the leading biopharma R&D organizations.

[Simon Barnett @SimonDBarnett]

Galileo's similarity theory powered centuries of industrialization, but living cells broke it.

In my newest essay, I argue that encoding this theory as an inductive bias is the only way to transform #bioprocess scaling from alchemy back into engineering.

[Frank Gao @ChemVagabond]

The full blog + code are now available. See https://t.co/s17UyByrMk

[Frank Gao @ChemVagabond]

We gave AI agents varying freedom to optimize models for protein thermostability prediction. They beat a 15x larger reference model, matched Bayesian optimization. And we learned a hybrid approach may work even better.

Blog: https://t.co/xGMrbVD5dn